Retrospective investigation of combination therapy with clarithromycin and levofloxacin for pulmonary Mycobacterium avium complex disease View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-09-03

AUTHORS

Hitoshi Shimomura, Airi Ono, Keiko Imanaka, Toru Majima, Hidenori Masuyama, Tsugumichi Sato, Takao Aoyama

ABSTRACT

BACKGROUND: Fluoroquinolones are often used for the treatment of refractory Mycobacterium avium complex (MAC) disease when the clinical efficacy of the recommended regimen, which includes clarithromycin (CAM), rifampicin (RFP), and ethambutol (EB), is insufficient. However, recent in vitro and in vivo studies have suggested that fluoroquinolones decreased the antibacterial activity of CAM when they were administered in combination. In this study, we retrospectively investigated the influence of the combination of CAM and levofloxacin (LVFX) on clinical outcomes for pulmonary MAC disease patients. METHODS: Pulmonary MAC disease patients from 2010 to 2012 were divided into two groups, those who received LVFX together with CAM (LVFX group) and those who received CAM without LVFX (control group). The number of patients who showed improvement was evaluated at 1, 3, 6 and 12 months after the start of therapy based on bacteriological examination (culture and smear examination) and the bacilli negative conversion rate. RESULTS: There were no significant differences between the LVFX group (n = 18, 64.5 ± 6.5 years old) and the control group (n = 57, 71.0 ± 7.0 years old) in terms of gender, age, etiologic agent, baseline culture examination score, concomitant medication, and dosage of each drug. The clinical outcomes in the LVFX group were inferior to those in the control group at all endpoints and observational periods, and we found a significant difference in the percent improvement of the smear examination by fluorescence microscopy method (38 % vs. 83 %) and the bacilli negative conversion rate (38 % vs. 79 %) at 3 months. Our study suggests that the combination of CAM and LVFX causes unfavorable clinical outcomes for pulmonary MAC disease treatment. There was no significant difference between both groups in terms of frequency of adverse events. CONCLUSION: The possibility that combined administration of CAM and LVFX causes unfavorable clinical outcomes for pulmonary MAC disease treatment was suggested. More... »

PAGES

24

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40780-015-0025-4

DOI

http://dx.doi.org/10.1186/s40780-015-0025-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018390361

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26819735


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan", 
          "id": "http://www.grid.ac/institutes/grid.143643.7", 
          "name": [
            "Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimomura", 
        "givenName": "Hitoshi", 
        "id": "sg:person.0713726041.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713726041.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan", 
          "id": "http://www.grid.ac/institutes/grid.143643.7", 
          "name": [
            "Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ono", 
        "givenName": "Airi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Chemotherapy Research Institute, Kaken Hospital, 6-1\u201314 Konodai, Ichikawa, Chiba 272-0827 Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Pharmacy, Chemotherapy Research Institute, Kaken Hospital, 6-1\u201314 Konodai, Ichikawa, Chiba 272-0827 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Imanaka", 
        "givenName": "Keiko", 
        "id": "sg:person.01030154441.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030154441.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory medicine, Chemotherapy Research Institute, Kaken Hospital, 6-1\u201314 Konodai, Ichikawa, Chiba 272-0827 Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Respiratory medicine, Chemotherapy Research Institute, Kaken Hospital, 6-1\u201314 Konodai, Ichikawa, Chiba 272-0827 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Majima", 
        "givenName": "Toru", 
        "id": "sg:person.01076267641.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076267641.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory medicine, Chemotherapy Research Institute, Kaken Hospital, 6-1\u201314 Konodai, Ichikawa, Chiba 272-0827 Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Respiratory medicine, Chemotherapy Research Institute, Kaken Hospital, 6-1\u201314 Konodai, Ichikawa, Chiba 272-0827 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masuyama", 
        "givenName": "Hidenori", 
        "id": "sg:person.01144403041.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144403041.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan", 
          "id": "http://www.grid.ac/institutes/grid.143643.7", 
          "name": [
            "Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sato", 
        "givenName": "Tsugumichi", 
        "id": "sg:person.014412762130.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014412762130.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan", 
          "id": "http://www.grid.ac/institutes/grid.143643.7", 
          "name": [
            "Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aoyama", 
        "givenName": "Takao", 
        "id": "sg:person.011206573461.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011206573461.15"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2015-09-03", 
    "datePublishedReg": "2015-09-03", 
    "description": "BACKGROUND: Fluoroquinolones are often used for the treatment of refractory Mycobacterium avium complex (MAC) disease when the clinical efficacy of the recommended regimen, which includes clarithromycin (CAM), rifampicin (RFP), and ethambutol (EB), is insufficient. However, recent in vitro and in vivo studies have suggested that fluoroquinolones decreased the antibacterial activity of CAM when they were administered in combination. In this study, we retrospectively investigated the influence of the combination of CAM and levofloxacin (LVFX) on clinical outcomes for pulmonary MAC disease patients.\nMETHODS: Pulmonary MAC disease patients from 2010 to 2012 were divided into two groups, those who received LVFX together with CAM (LVFX group) and those who received CAM without LVFX (control group). The number of patients who showed improvement was evaluated at 1, 3, 6 and 12\u00a0months after the start of therapy based on bacteriological examination (culture and smear examination) and the bacilli negative conversion rate.\nRESULTS: There were no significant differences between the LVFX group (n\u2009=\u200918, 64.5\u2009\u00b1\u20096.5\u00a0years old) and the control group (n\u2009=\u200957, 71.0\u2009\u00b1\u20097.0\u00a0years old) in terms of gender, age, etiologic agent, baseline culture examination score, concomitant medication, and dosage of each drug. The clinical outcomes in the LVFX group were inferior to those in the control group at all endpoints and observational periods, and we found a significant difference in the percent improvement of the smear examination by fluorescence microscopy method (38\u00a0% vs. 83\u00a0%) and the bacilli negative conversion rate (38\u00a0% vs. 79\u00a0%) at 3\u00a0months. Our study suggests that the combination of CAM and LVFX causes unfavorable clinical outcomes for pulmonary MAC disease treatment. There was no significant difference between both groups in terms of frequency of adverse events.\nCONCLUSION: The possibility that combined administration of CAM and LVFX causes unfavorable clinical outcomes for pulmonary MAC disease treatment was suggested.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40780-015-0025-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1052798", 
        "issn": [
          "2055-0294"
        ], 
        "name": "Journal of Pharmaceutical Health Care and Sciences", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "1"
      }
    ], 
    "keywords": [
      "Mycobacterium avium complex disease", 
      "combination of clarithromycin", 
      "avium complex disease", 
      "negative conversion rate", 
      "unfavorable clinical outcome", 
      "clinical outcomes", 
      "LVFX group", 
      "disease patients", 
      "pulmonary Mycobacterium avium complex disease", 
      "control group", 
      "significant differences", 
      "start of therapy", 
      "administration of clarithromycin", 
      "number of patients", 
      "disease treatment", 
      "concomitant medications", 
      "adverse events", 
      "clinical efficacy", 
      "combination therapy", 
      "smear examination", 
      "complex diseases", 
      "retrospective investigation", 
      "etiologic agent", 
      "clarithromycin", 
      "bacteriological examination", 
      "levofloxacin", 
      "patients", 
      "vivo studies", 
      "outcomes", 
      "ethambutol", 
      "therapy", 
      "observational period", 
      "treatment", 
      "examination scores", 
      "disease", 
      "months", 
      "fluoroquinolones", 
      "rifampicin", 
      "conversion rate", 
      "group", 
      "terms of gender", 
      "examination", 
      "percent improvement", 
      "regimen", 
      "medications", 
      "antibacterial activity", 
      "terms of frequency", 
      "differences", 
      "administration", 
      "study", 
      "endpoint", 
      "drugs", 
      "efficacy", 
      "age", 
      "scores", 
      "dosage", 
      "rate", 
      "gender", 
      "improvement", 
      "combination", 
      "agents", 
      "period", 
      "activity", 
      "start", 
      "events", 
      "frequency", 
      "number", 
      "fluorescence microscopy methods", 
      "investigation", 
      "possibility", 
      "terms", 
      "method", 
      "influence", 
      "microscopy methods", 
      "refractory Mycobacterium avium complex (MAC) disease", 
      "pulmonary MAC disease patients", 
      "MAC disease patients", 
      "bacilli negative conversion rate", 
      "baseline culture examination score", 
      "culture examination score", 
      "pulmonary MAC disease treatment", 
      "MAC disease treatment"
    ], 
    "name": "Retrospective investigation of combination therapy with clarithromycin and levofloxacin for pulmonary Mycobacterium avium complex disease", 
    "pagination": "24", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018390361"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40780-015-0025-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26819735"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40780-015-0025-4", 
      "https://app.dimensions.ai/details/publication/pub.1018390361"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_652.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40780-015-0025-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40780-015-0025-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40780-015-0025-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40780-015-0025-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40780-015-0025-4'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      108 URIs      100 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40780-015-0025-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N15a96a74e27c4bb3bcb2e9a9c75f399a
4 schema:datePublished 2015-09-03
5 schema:datePublishedReg 2015-09-03
6 schema:description BACKGROUND: Fluoroquinolones are often used for the treatment of refractory Mycobacterium avium complex (MAC) disease when the clinical efficacy of the recommended regimen, which includes clarithromycin (CAM), rifampicin (RFP), and ethambutol (EB), is insufficient. However, recent in vitro and in vivo studies have suggested that fluoroquinolones decreased the antibacterial activity of CAM when they were administered in combination. In this study, we retrospectively investigated the influence of the combination of CAM and levofloxacin (LVFX) on clinical outcomes for pulmonary MAC disease patients. METHODS: Pulmonary MAC disease patients from 2010 to 2012 were divided into two groups, those who received LVFX together with CAM (LVFX group) and those who received CAM without LVFX (control group). The number of patients who showed improvement was evaluated at 1, 3, 6 and 12 months after the start of therapy based on bacteriological examination (culture and smear examination) and the bacilli negative conversion rate. RESULTS: There were no significant differences between the LVFX group (n = 18, 64.5 ± 6.5 years old) and the control group (n = 57, 71.0 ± 7.0 years old) in terms of gender, age, etiologic agent, baseline culture examination score, concomitant medication, and dosage of each drug. The clinical outcomes in the LVFX group were inferior to those in the control group at all endpoints and observational periods, and we found a significant difference in the percent improvement of the smear examination by fluorescence microscopy method (38 % vs. 83 %) and the bacilli negative conversion rate (38 % vs. 79 %) at 3 months. Our study suggests that the combination of CAM and LVFX causes unfavorable clinical outcomes for pulmonary MAC disease treatment. There was no significant difference between both groups in terms of frequency of adverse events. CONCLUSION: The possibility that combined administration of CAM and LVFX causes unfavorable clinical outcomes for pulmonary MAC disease treatment was suggested.
7 schema:genre article
8 schema:inLanguage en
9 schema:isAccessibleForFree true
10 schema:isPartOf Nc36c62a43acd43aa8d81e3ea4e9d7b0f
11 Nd267ccec7a1a45479994d33a7f458282
12 sg:journal.1052798
13 schema:keywords LVFX group
14 MAC disease patients
15 MAC disease treatment
16 Mycobacterium avium complex disease
17 activity
18 administration
19 administration of clarithromycin
20 adverse events
21 age
22 agents
23 antibacterial activity
24 avium complex disease
25 bacilli negative conversion rate
26 bacteriological examination
27 baseline culture examination score
28 clarithromycin
29 clinical efficacy
30 clinical outcomes
31 combination
32 combination of clarithromycin
33 combination therapy
34 complex diseases
35 concomitant medications
36 control group
37 conversion rate
38 culture examination score
39 differences
40 disease
41 disease patients
42 disease treatment
43 dosage
44 drugs
45 efficacy
46 endpoint
47 ethambutol
48 etiologic agent
49 events
50 examination
51 examination scores
52 fluorescence microscopy methods
53 fluoroquinolones
54 frequency
55 gender
56 group
57 improvement
58 influence
59 investigation
60 levofloxacin
61 medications
62 method
63 microscopy methods
64 months
65 negative conversion rate
66 number
67 number of patients
68 observational period
69 outcomes
70 patients
71 percent improvement
72 period
73 possibility
74 pulmonary MAC disease patients
75 pulmonary MAC disease treatment
76 pulmonary Mycobacterium avium complex disease
77 rate
78 refractory Mycobacterium avium complex (MAC) disease
79 regimen
80 retrospective investigation
81 rifampicin
82 scores
83 significant differences
84 smear examination
85 start
86 start of therapy
87 study
88 terms
89 terms of frequency
90 terms of gender
91 therapy
92 treatment
93 unfavorable clinical outcome
94 vivo studies
95 schema:name Retrospective investigation of combination therapy with clarithromycin and levofloxacin for pulmonary Mycobacterium avium complex disease
96 schema:pagination 24
97 schema:productId N027a862cf75340229e671f0354bb5671
98 N6aa44c3fed6b427388ec1c7fc8eca55f
99 Nf684292f44bf455fa98238dade039b38
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018390361
101 https://doi.org/10.1186/s40780-015-0025-4
102 schema:sdDatePublished 2021-11-01T18:24
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher N88434815242b4706b3e8435f2db1ce73
105 schema:url https://doi.org/10.1186/s40780-015-0025-4
106 sgo:license sg:explorer/license/
107 sgo:sdDataset articles
108 rdf:type schema:ScholarlyArticle
109 N027a862cf75340229e671f0354bb5671 schema:name pubmed_id
110 schema:value 26819735
111 rdf:type schema:PropertyValue
112 N046bb3d686a6493dab8ab677353f5efc rdf:first Nd6d51e10b3c241e6a8bda4d0d95def49
113 rdf:rest Neba21ccaf26e4dfa81b58580697c705c
114 N15a96a74e27c4bb3bcb2e9a9c75f399a rdf:first sg:person.0713726041.31
115 rdf:rest N046bb3d686a6493dab8ab677353f5efc
116 N6aa44c3fed6b427388ec1c7fc8eca55f schema:name dimensions_id
117 schema:value pub.1018390361
118 rdf:type schema:PropertyValue
119 N803ccdb857c4465fbad0ccd8249608f9 rdf:first sg:person.01144403041.34
120 rdf:rest N95c13be61ce14e04b35275e199bee2d0
121 N8539ecf6ba5d46e1b02ddac78b825f10 rdf:first sg:person.01076267641.51
122 rdf:rest N803ccdb857c4465fbad0ccd8249608f9
123 N88434815242b4706b3e8435f2db1ce73 schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 N95c13be61ce14e04b35275e199bee2d0 rdf:first sg:person.014412762130.28
126 rdf:rest N973de838098a4d0fb119badb667f2ac7
127 N973de838098a4d0fb119badb667f2ac7 rdf:first sg:person.011206573461.15
128 rdf:rest rdf:nil
129 Nc36c62a43acd43aa8d81e3ea4e9d7b0f schema:issueNumber 1
130 rdf:type schema:PublicationIssue
131 Nd267ccec7a1a45479994d33a7f458282 schema:volumeNumber 1
132 rdf:type schema:PublicationVolume
133 Nd6d51e10b3c241e6a8bda4d0d95def49 schema:affiliation grid-institutes:grid.143643.7
134 schema:familyName Ono
135 schema:givenName Airi
136 rdf:type schema:Person
137 Neba21ccaf26e4dfa81b58580697c705c rdf:first sg:person.01030154441.47
138 rdf:rest N8539ecf6ba5d46e1b02ddac78b825f10
139 Nf684292f44bf455fa98238dade039b38 schema:name doi
140 schema:value 10.1186/s40780-015-0025-4
141 rdf:type schema:PropertyValue
142 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
143 schema:name Medical and Health Sciences
144 rdf:type schema:DefinedTerm
145 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
146 schema:name Clinical Sciences
147 rdf:type schema:DefinedTerm
148 sg:journal.1052798 schema:issn 2055-0294
149 schema:name Journal of Pharmaceutical Health Care and Sciences
150 schema:publisher Springer Nature
151 rdf:type schema:Periodical
152 sg:person.01030154441.47 schema:affiliation grid-institutes:None
153 schema:familyName Imanaka
154 schema:givenName Keiko
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030154441.47
156 rdf:type schema:Person
157 sg:person.01076267641.51 schema:affiliation grid-institutes:None
158 schema:familyName Majima
159 schema:givenName Toru
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076267641.51
161 rdf:type schema:Person
162 sg:person.011206573461.15 schema:affiliation grid-institutes:grid.143643.7
163 schema:familyName Aoyama
164 schema:givenName Takao
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011206573461.15
166 rdf:type schema:Person
167 sg:person.01144403041.34 schema:affiliation grid-institutes:None
168 schema:familyName Masuyama
169 schema:givenName Hidenori
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144403041.34
171 rdf:type schema:Person
172 sg:person.014412762130.28 schema:affiliation grid-institutes:grid.143643.7
173 schema:familyName Sato
174 schema:givenName Tsugumichi
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014412762130.28
176 rdf:type schema:Person
177 sg:person.0713726041.31 schema:affiliation grid-institutes:grid.143643.7
178 schema:familyName Shimomura
179 schema:givenName Hitoshi
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713726041.31
181 rdf:type schema:Person
182 grid-institutes:None schema:alternateName Department of Pharmacy, Chemotherapy Research Institute, Kaken Hospital, 6-1–14 Konodai, Ichikawa, Chiba 272-0827 Japan
183 Department of Respiratory medicine, Chemotherapy Research Institute, Kaken Hospital, 6-1–14 Konodai, Ichikawa, Chiba 272-0827 Japan
184 schema:name Department of Pharmacy, Chemotherapy Research Institute, Kaken Hospital, 6-1–14 Konodai, Ichikawa, Chiba 272-0827 Japan
185 Department of Respiratory medicine, Chemotherapy Research Institute, Kaken Hospital, 6-1–14 Konodai, Ichikawa, Chiba 272-0827 Japan
186 rdf:type schema:Organization
187 grid-institutes:grid.143643.7 schema:alternateName Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan
188 schema:name Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...